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Abstract
Translation and cross-cultural adaptation of the 39-item Parkinson’s Disease Questionnaire (PDQ-39) to the Italian culture was
performed by Oxford University Innovation in 2008, but this version has never been validated. Therefore, we performed the
process of validation of the Italian version of the PDQ-39 (PDQ-39-IT) following the BConsensus-Based Standards for the
Selection of Health Status Measurement Instruments^ checklist. The translated PDQ-39-IT was tested with 104 patients diag-
nosed with Parkinson’s disease (PD) who were recruited between June and October 2017. The mean age of the participants was
65.7 ± 10.2 years, and the mean duration of symptoms was 7.4 ± 5.3 years. The internal consistency of the PDQ-39-IT was
assessed by Cronbach’s alpha and ranged from 0.69 to 0.92. In an assessment of test-retest reliability in 35 of the 104 patients, the
infraclass correlation coefficient (ICC) ranged from 0.85 to 0.96 for the various subitems of the PDQ-39-IT (all p < 0.01).
Spearman’s rank correlation coefficient for the validity of the PDQ-39-IT and the Italian version of the 36-Item Short Form
(SF-36) was − 0.50 (p < 0.01). The results show that the PDQ-39-IT is a reliable and valid tool to assess the impact of PD on
functioning and well-being. Thus, the PDQ-39-IT can be used in clinical and research practice to assess this construct and to
evaluate the overall effect of different treatments in Italian PD patients.
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Introduction
Parkinson’s disease (PD) is a common progressive, neuro-
degenerative disease, affecting 0.1% of the general
population and 1% of the population over 65 years [1]. In
2016, the estimated regional incidence rate of PD in Italy
was 0.28 new cases/1000 person-years, with a prevalence of
3.89/1000 persons [2]. The disease incidence increases with
older age and is more common among males than females
[3, 4]. The clinical, social, and economic implications of PD
are significant. Disability in PD is due to the presence of
both motor and non-motor symptoms, which restrict both
the self-sufficiency and social participation of patients,
leading to a low quality of life (QoL) for both patients and
their caregivers.
Several scales have been proposed to assess the QoL of PD
patients [5]. Information on the QoL of PD patients and stud-
ies on the relationship between QoL and motor and cognitive
functions are necessary both for research and clinical use to
make informed decisions in healthcare and rehabilitation areas
[6–8]. In a systematic review, Martinez-Martin et al. [9] con-
cluded that four generic scales (EuroQoL [10], Nottingham
Health Profile [11], 36-Item Short Form Health Survey (SF-
36) [12], and Sickness Impact Profile [13]) and five specific
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scales (Parkinson’s Disease Questionnaire Short Form [14],
Parkinson’s Disease Quality of Life Questionnaire [15],
Parkinson’s Impact Scale [16], Scales for Outcomes in
Parkinson’s Disease-Psychosocial [17], and the 39-Item
Parkinson’s Disease Questionnaire (PDQ-39) [18, 19]) could
be recommended. The PDQ-39, developed in 1995 by Peto et
al. [18, 19], is the most thoroughly tested and applied assess-
ment tool to assess QoL in PD patients. The questionnaire
consists of 39 items, divided into 8 subtests: mobility (10
items), activities of daily living (6 items), emotional well-
being (6 items), stigma (4 items), social support (3 items),
cognition (4 items), communication (3 items), and bodily dis-
comfort (3 items). For each item, there are five possible an-
swers: never, occasionally, sometimes, often, and always. The
PDQ-39 is a patient-assessed instrument, which reflects the
entire spectrum of health-related quality of life in PD patients,
and research has shown that it is feasible, reliable, valid, com-
prehensive, and sensitive to change. The PDQ-39 is widely
used worldwide, and it has been translated, culturally adapted,
and validated into 13 different languages: English [18, 19],
Spanish [20], American [21, 22], Greek [23], Chinese
[24–26], Singaporean [27], Ecuadorian [28], French [29],
Brazilian [30], Estonian [31], Iranian [32], Korean [33, 34],
and Portuguese [35]. For the development of clinical practice
and research in the field of PD, a practical and appropriate
measurement scale is needed that is universally accepted.
The goal shared by all health professions that deal with PD
is improvement of QoL. To achieve this goal, instruments
used in assessing the QoL in PD patients must be practical,
appropriate, and validated for clinical use. The latter is also
required to allow comparisons and meta-analyses of high-
quality randomized controlled trials of individuals with PD.
In 2008, Oxford University Innovation, (https://innovation.
ox.ac.uk/), a subsidiary of the University of Oxford in the UK
(https://innovation.ox.ac.uk/), accepted a translated and
adapted version of the PDQ-39 in Italian. However, the psy-
chometric properties of the Italian translated version of the
PDQ-39 (PDQ-29-IT) have not been evaluated. Therefore,
the aim of this study was to review the PDQ-39-IT and to
evaluate its psychometric properties.
Methods
This study was conducted by a research group composed
by medical doctors and rehabilitation professionals from
the BSap ienza^ Unive r s i t y o f Rome and f rom
BRehabilitation & Outcome Measure Assessment^
(R.O.M.A.) association. R.O.M.A. association in the last
few years has dealt with the validation of many outcome
measures in Italy [36–44]. We contacted the developers of
the PDQ-39 to obtain permission to use the scale. We
were informed that Oxford University Innovation, the
copyright holder, had already accepted a translated and
adapted version of the PDQ-39 in Italian. After receiving
the consent of Oxford University Innovation (https://
innovation.ox.ac.uk/) in accordance with established
guidelines [45], a focus group composed of one
neurologist, one occupational therapist, and two
physiotherapists assessed the level of comprehensibility
and cognitive equivalence of the translated version
(PDQ-39-IT) and verified the presence of possible
confusing issues.
SampleAccording to previous validations of the tool [18–35],
a minimum sample size of 86 participants with PD was re-
quired. The diagnosis of PD was based on the clinical diag-
nostic criteria of the Movement Disorder Society for PD [35].
We included patients older than 40 years, with a Mini-Mental
State Examination score of ≥ 23 points [46, 47] and a mini-
mum level of 5 years of education.
Consecutive individuals with PD were recruited from June
to October 2017 from two University Hospitals in Rome, Italy
(Sapienza University and Tor Vergata University). Eligible
participants who met the inclusion criteria were informed
about the study and invited to take part. All the participants
included provided consent prior to the commencement of the
study [48].
Measurements For each participant, the following demo-
graphic information was recorded: age, sex, years of educa-
tion, employment status, disease duration (years), and disease
severity according to the Hoehn and Yahr (H&Y) scale [49].
The PDQ-39 and SF-36 [12, 50] were used as outcome
measures. SF-36 is a self-administered questionnaire designed
to assess the health status of patients and has been validated
for use in clinical practice and research [50].
Reliability and validity The reliability and validity of the
culturally adapted scale (PDQ-39-IT) were assessed fol-
lowing the BConsensus-Based Standards for the Selection
of Health Status Measurement Instruments^ checklist [51].
For the assessment of test-retest reliability, a subgroup of
patients was evaluated twice by the same examiner. The
time interval between the test and retest was 3 days to
ensure that the clinical condition of the patient remained
stable. The retest was performed in person or by telephone
interview. Test-retest reliability was measured by calculat-
ing the intraclass correlation coefficient (ICC). The scale
was considered reliable at an ICC of > 0.70.
The internal consistency of the PDQ-39-IT was evaluated
by Cronbach’s alpha, which was considered statistically sig-
nificant at a cut-off of > 0.70. Following the procedures of the
original validation of the scale, we compared the scores of the
PDQ-39-ITwith those obtained with the Italian version of SF-
36 using the Spearman’s rank correlation coefficient.
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Data availability The PDQ-39-IT validated in this study is avail-
able in accordance with the copyright owner’s royalties
(process.innovation.ox.ac.uk/clinical/p/pdq-39/questionnaire/1).
Results
The focus group session ensured that all the items in the PDQ-
39-IT were similar or identical to the original English version
of the tool [21]. In total, 112 individuals were considered
eligible for inclusion in the study. Of these, 104 individuals
agreed to participate and were enrolled. All 104 participants
completed the study. Demographic data of the patients studied
are presented in Table 1.
Reliability The internal consistency of the PDQ-39-IT, as
assessed by Cronbach’s alpha, ranged from 0.69 to 0.92.
The lower of these two values (i.e., 0.69) was obtained in
the social support dimension, and the higher values (i.e.,
0.92) were obtained in the mobility dimension. The di-
mensions of stigma and cognition were at the cut-off limit
of 0.70. The other dimensions of activities of daily living,
emotional well-being, communication, and bodily dis-
comfort ranged from 0.76 and 0.87. Data on the internal
consistency and reliability are summarized in Table 2.
In 35 of the 104 patients enrolled in the study, the
PDQ-39-IT was administered twice, with an interval of
3 days between the tests. As shown by the ICCs,
intrarater reliability ranged from 0.85 to 0.96, with a
high level of agreement between the two ratings, (all p
< 0.001). The test-retest reliability data are summarized
in Table 3.
Due to the small number of patients in each of the H&Y
stages, we could not perform a correlational analysis between
disease severity as assessed by the H&Y stages and the scores
of the various subitems of the PDQ-39-IT.
Validity Spearman’s rank correlation coefficient for the valid-
ity of the PDQ-39-IT and the Italian version of the SF-36 was
− 0.50 (p < 0.01).
All dimensions of the PDQ-39-IT showed a positive and
significant association with all the dimensions of the SF-36
questionnaire [12, 50]. The mean scores and correlation of
both tools are reported in Tables 4 and 5.
Discussion
The quality of life in PD has been the focus of much
interest [51–54]. To assess quality of life, a valid and
Table 2 Internal consistency
reliability of Italian PDQ-39 Subtest Number of items Cronbach’s alpha Mean ± SD SD
Mobility 10 0.92 15.63 10.59
ADL 6 0.87 8.72 6.25
Emotional well-being 6 0.80 9.46 5.33
Stigma 4 0.70 4.45 3.70
Social support 3 0.69 1.65 2.29
Cognitions 4 0.70 4.88 3.47
Communication 3 0.76 3.08 2.85
Bodily discomfort 3 0.76 4.55 3.13
Table 1 Demographic characteristics of patients enrolled
Variable Mean ± SD Frequency (%) Range
Gender
Men 64 (62)
Women 40 (38)
Age 65.7 ± 10.2 42–90
Symptoms
duration (years)
7.4 ± 5.3 0–26
MMSE 28.4 ± 1.8 23–30
H&Y
I 9 (8.6) 1–4
II 33 (31.7)
III 45 (43.2)
IV 17 (16.3)
Education
Primary school 8 (7.6)
Middle school 33 (31.7)
High school 45 (43.2)
Graduated 18 (17.3)
Employment status
Employed 28 (27)
Unemployed 6 (6)
Retired 70 (67)
Marital status
Married 77 (74.0)
Unmarried 27 (26.0)
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reliable tool is needed that can be used worldwide. The
present study assessed the psychometric properties of
PDQ-39-IT.
In this study, we showed that the PDQ-39-IT displays
satisfactory psychometric properties, namely good reli-
ability and validity. The Cronbach’s alpha coefficients in
the present study (range of 0.69 to 0.92) were similar to
those found by Peto et al. [18] in the original validation
study and to those of the original British version [19].
They were also similar to those obtained in most transla-
tions [18–35] and validation studies [20, 26–28, 30, 31].
In this study, the Cronbach’s alpha coefficient for the so-
cial support subtest was < 0.70, suggesting that this
dimension may not provide accurate data. However, the
test-retest reliability of each subitem of the scale was re-
liable, as shown by the ICCs. In common with the origi-
nal UK study [18], we used the Italian version of SF-36
[43] as a gold standard to assess construct validity.
Among the eight dimensions of the PDQ-39, Spearman’s
rank correlation coefficients for the total score of the SF-
36 were significant [50]. Most previous validation studies
of the PDQ-39 in other cultural settings used a variety of
rating scales and classifications to assess construct valid-
ity [18–35]. All these studies found statistically signifi-
cant correlations between disease severity and some of
the PDQ-39 domains.
Table 3 Test-retest reliability of
Italian PDQ-39 Intraclass correlation 95% confidence interval
Lower bound Upper bound Value Sig
Mobility 0.94 0.88 0.97 16.43 0.000
ADL 0.94 0.88 0.97 16.55 0.000
Emotional well-being 0.91 0.82 0.96 11.23 0.000
Stigma 0.91 0.82 0.96 11.18 0.000
Social support 0.85 0.71 0.93 6.80 0.000
Cognition 0.93 0.87 0.97 14.91 0.000
Communication 0.91 0.82 0.96 11.25 0.000
Bodily discomfort 0.96 0.93 0.98 28.07 0.000
Table 4 PDQ-39-IT and SF-36
mean scores Min Max Mean SD
Total 8 128 52.38 28.66
Tot. mobility (1–10) 0 39 15.63 10.59
Tot. ADL (11–16) 0 24 8.80 6.27
Tot. emotional well-being (17–22) 0 22 9.37 5.36
Tot. stigma (23–26) 0 14 4.43 3.68
Tot. social support (27–29) 0 9 1.65 2.29
Tot. cognitions (30–33) 0 15 4.88 3.47
Tot. communication (34–36) 0 11 3.08 2.85
Tot. bodily discomfort (37–39) 0 8 3.57 2.23
Total 62 118 96.93 10.19
Tot. physical functions (3–12) 10 30 21.19 5.96
Tot. role physical limitations for discomfort
Limit. ruolo disagi fisici (13–16)
3 8 5.31 1.54
Tot. pain dolore (21–22) 2 11 5.83 2.49
Tot. general health (1. 33–36) 4 24 16.97 2.92
Tot. vitality (23.27.29.31) 4 22 15.17 3.28
Tot. social function (20.32) 1 8 5.63 1.06
Tot. role limitations emotional for distress (17–19) 0 6 4.18 1.37
Tot. mental health (2.24.25.26.28.30) 8 29 22.64 3.59
Neurol Sci
Limitations of the study
A limitation of our study is that we were unable to correlate
PDQ domains and disease severity due to the small number of
subjects in each H&Y stage. The distribution of patients by
severity was unbalanced (fewer patients with stages I and IV).
In addition, patients were recruited from two university hos-
pitals in Rome, and therefore we cannot exclude that the re-
sults we obtained in these settings could be different from
those obtained in other geographical areas. To overcome this
limitation, future studies should include larger samples of PD
patients from different areas throughout Italy with better bal-
anced distribution of severity.
Conclusions
In conclusion, the PDQ-39-IT is an acceptable, valid, and
reliable tool to measure the quality of life of Italian PD pa-
tients. It provides Italian clinicians with a valid, reliable, rap-
idly administrable, and standardized scale to measure quality
of life in PD, thereby enabling clinicians in all healthcare and
rehabilitation professions to make informed decisions. It also
provides Italian researchers with a PD assessment tool that is
used worldwide and that can be employed in high-quality and
comparable randomized controlled trials.
Compliance with ethical standards
All the participants included provided consent prior to the commence-
ment of the study [48].
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